RETRACTED: Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score–Matched Study of 1,008 Patients
Journal of Vascular and Interventional Radiology · 2025
DOI: 10.1016/j.jvir.2024.09.005 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Vascular and Interventional Radiology, 2025. Verfasst von Hongmin Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Propensity Score. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To assess the effectiveness of transarterial bland embolization (TAE) compared with transarterial chemoembolization (TACE) therapy in the treatment of patients with intermediate-stage hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Two thousand two hundred ninety-seven patients with intermediate-stage HCC were screened, and 1,461 patients who underwent TAE or TACE as the first-choice treatment were retrospectively analyzed and baseline matched according to the 2 treatment methods. Subgroup analysis was performed among patients according to the Up-to-7 criteria. The primary endpoint was overall survival (OS). RESULTS: A total of 1,461 patients with HCC who underwent TAE or TACE were included; 730 patients underwent TACE and 731 underwent TAE. The patients in the TAE group exhibited poorer liver function and a significantly higher rate of hepatitis B infection (P < .001) compared with the TACE group. After propensity score matching, 504 well-matched pairs of patients with intermediate-stage HCC were selected for analysis. Univariate analysis showed that TACE significantly prolonged patient survival compared with TAE (P < .001). The 1-, 2-, and 3-year OS rates were 74.3%, 57.1%, and 44.4% and for the TACE group and 58.3%, 32.4%, and 21.7% for the TAE group, respectively. Multivariate analysis showed a hazard ratio of 0.517 (95% CI, 0.442-0.605; P < .001) for the TACE approach over the TAE approach for OS. The TACE group had a significantly higher overall response rate than the TAE group (35% vs 26%; P = .024). CONCLUSIONS: TACE resulted in higher response rate and longer OS compared with TAE as the initial treatment for intermediate-stage HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, People's Republic of China.
- Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; State Key Laboratory of Oncology in South China, Collaborative Innovation Center of C…
Zitieren
APA
Zhang, H., Xu, J., Meng, H., & Shen, L. (2025). RETRACTED: Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score–Matched Study of 1,008 Patients. Journal of Vascular and Interventional Radiology. https://doi.org/10.1016/j.jvir.2024.09.005
Vancouver
Zhang H, Xu J, Meng H, Shen L. RETRACTED: Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score–Matched Study of 1,008 Patients. Journal of Vascular and Interventional Radiology. 2025. doi:10.1016/j.jvir.2024.09.005
BibTeX
@article{Zhang2025,
author = {Zhang, Hongmin and Xu, Jian and Meng, Haoyu and Shen, Lujun},
title = {RETRACTED: Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score–Matched Study of 1,008 Patients},
journal = {Journal of Vascular and Interventional Radiology},
year = {2025},
doi = {10.1016/j.jvir.2024.09.005}
}
EUVIMED